Overview Dividends

(CMPS) Compass Pathways - Ratings and Ratios

Exchange: NASDAQ • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US20451W1018

Psilocybin Therapy, Phase III, Depression, PTSD

CMPS EPS (Earnings per Share)

EPS Growth (3Y CAGR): 161.32%
EPS Trend (3Y Correlation): 72.4%

CMPS Revenue

Revenue Growth (3Y CAGR): 0.00%
Revenue Trend (3Y Correlation): -4.4%

Description: CMPS Compass Pathways October 27, 2025

Compass Pathways plc (NASDAQ: CMPS) is a London-based biotech focused on developing psilocybin-based therapies for mental-health disorders. Its lead asset, COMP360, is in a pivotal Phase III trial for treatment-resistant depression (TRD) and advancing through Phase II studies for post-traumatic stress disorder (PTSD) and anorexia nervosa. The company, originally incorporated as COMPASS Rx Limited in 2020, rebranded to its current name in August 2020 and operates primarily in the United Kingdom and the United States.

Key quantitative points: as of the latest filing, Compass reported a cash runway of roughly $150 million, supporting its R&D pipeline through at least 2026; the Phase III TRD trial received FDA Breakthrough Therapy designation in 2022, a status that historically accelerates review timelines and can enhance valuation multiples; the global mental-health market is projected to exceed $200 billion by 2030, with psychedelics poised to capture a growing share as regulatory frameworks evolve, especially after the FDA’s recent acceptance of psilocybin-assisted therapy data. Market-cap estimates currently hover around $500 million, but the stock’s volatility reflects uncertainty around trial outcomes and potential reimbursement pathways.

If you’re looking for a data-driven, risk-adjusted view of CMPS’s upside, the analyst models on ValueRay provide a useful starting point for deeper research.

CMPS Stock Overview

Market Cap in USD	606m
Sub-Industry	Health Care Services
IPO / Inception	2020-09-18

CMPS Stock Ratings

Growth Rating	-14.9%
Fundamental	32.0%
Dividend Rating	-
Return 12m vs S&P 500	18.1%
Analyst Rating	4.64 of 5

CMPS Dividends

Currently no dividends paid

CMPS Growth Ratios

Growth Correlation 3m	92.3%
Growth Correlation 12m	36.2%
Growth Correlation 5y	-93%
CAGR 5y	-11.15%
CAGR/Max DD 3y (Calmar Ratio)	-0.14
CAGR/Mean DD 3y (Pain Ratio)	-0.27
Sharpe Ratio 12m	0.38
Alpha	-0.48
Beta	2.224
Volatility	69.96%
Current Volume	12414.3k
Average Volume 20d	1559.9k
Stop Loss	6.1 (-8%)
Signal	2.68

Piotroski VR‑10 (Strict, 0-10) 0.0

error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM)

FCFTA -0.51 (>2.0%) and ΔFCFTA -14.55pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev)

CFO/TA -0.51 (>3.0%) and CFO -148.3m <= Net Income -138.6m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 8.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (93.3m) change vs 12m ago 36.52% (target <= -2.0% for YES)

error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue)

Asset Turnover 0.0% (prev 1.32%; Δ -1.32pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -30.97 (EBITDA TTM -140.8m / Interest Expense TTM 4.56m) >= 6 (WARN >= 3)

Altman Z'' -9.25

(A) 0.83 = (Total Current Assets 276.4m - Total Current Liabilities 31.3m) / Total Assets 293.5m

(B) -2.01 = Retained Earnings (Balance) -591.0m / Total Assets 293.5m

warn (B) unusual magnitude: -2.01 — check mapping/units

(D) -4.62 = Book Value of Equity -604.6m / Total Liabilities 131.0m

Total Rating: -9.25 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 32.03

1. Piotroski 0.0pt = -5.0

2. FCF Yield -35.36% = -5.0

3. FCF Margin data missing

4. Debt/Equity 0.22 = 2.48

5. Debt/Ebitda 1.33 = 1.26

6. ROIC - WACC (= -75.19)% = -12.50

7. RoE -78.53% = -2.50

8. Rev. Trend -4.37% = -0.33

9. EPS Trend 72.45% = 3.62

What is the price of CMPS shares?

As of November 05, 2025, the stock is trading at USD 6.63 with a total of 12,414,323 shares traded.
Over the past week, the price has changed by +1.22%, over one month by +5.41%, over three months by +44.13% and over the past year by +41.67%.

Is Compass Pathways a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Compass Pathways (NASDAQ:CMPS) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 32.03 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CMPS is around 6.01 USD . This means that CMPS is currently overvalued and has a potential downside of -9.35%.

Is CMPS a buy, sell or hold?

Compass Pathways has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy CMPS.

Strong Buy: 7
Buy: 4
Hold: 0
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the CMPS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	15.6	135.3%
Analysts Target Price	15.6	135.3%
ValueRay Target Price	7	5.7%

CMPS Fundamental Data Overview November 02, 2025

Market Cap USD = 606.3m (606.3m USD * 1.0 USD.USD)
P/B = 3.5472
Beta = 2.224
Revenue TTM = 0.0 USD
EBIT TTM = -141.2m USD
EBITDA TTM = -140.8m USD
Long Term Debt = 23.0m USD (from longTermDebt, last quarter)
Short Term Debt = 10.0m USD (from shortTermDebt, last quarter)
Debt = 35.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -187.0m USD (from netDebt column, last quarter)
Enterprise Value = 419.4m USD (606.3m + Debt 35.3m - CCE 222.3m)
Interest Coverage Ratio = -30.97 (Ebit TTM -141.2m / Interest Expense TTM 4.56m)
FCF Yield = -35.36% (FCF TTM -148.3m / Enterprise Value 419.4m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 159.9k) / Revenue TTM)
Tobins Q-Ratio = 1.43 (Enterprise Value 419.4m / Total Assets 293.5m)
Interest Expense / Debt = 3.30% (Interest Expense 1.16m / Debt 35.3m)
Taxrate = 9.75% (-4.20m / -43.1m)
NOPAT = -127.4m (EBIT -141.2m * (1 - 9.75%)) [loss with tax shield]
Current Ratio = 8.82 (Total Current Assets 276.4m / Total Current Liabilities 31.3m)
Debt / Equity = 0.22 (Debt 35.3m / totalStockholderEquity, last quarter 162.6m)
Debt / EBITDA = 1.33 (negative EBITDA) (Net Debt -187.0m / EBITDA -140.8m)
Debt / FCF = 1.26 (negative FCF - burning cash) (Net Debt -187.0m / FCF TTM -148.3m)
Total Stockholder Equity = 176.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -47.20% (Net Income -138.6m / Total Assets 293.5m)
RoE = -78.53% (Net Income TTM -138.6m / Total Stockholder Equity 176.4m)
RoCE = -70.79% (EBIT -141.2m / Capital Employed (Equity 176.4m + L.T.Debt 23.0m))
RoIC = -61.60% (negative operating profit) (NOPAT -127.4m / Invested Capital 206.8m)
WACC = 13.59% (E(606.3m)/V(641.6m) * Re(14.21%) + D(35.3m)/V(641.6m) * Rd(3.30%) * (1-Tc(0.10)))
Discount Rate = 14.21% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 26.30%
Fair Price DCF = unknown (Cash Flow -148.3m)
EPS Correlation: 72.45 | EPS CAGR: 161.3% | SUE: 3.63 | # QB: 1
Revenue Correlation: -4.37 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0

Additional Sources for CMPS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle